Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin

Diabetes Care

Volumn 25, Issue 7, 2002, Pages 1123-1128

  Miles, John M ^a,b   Leiter, Lawrence ^a   Hollander, Priscilla ^a   Wadden, Thomas ^a   Anderson, James W ^a   Doyle, Michael ^a   Foreyt, John ^a   Aronne, Louis ^a   Klein, Samuel ^a  

^a St Lukes Hospital   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME INHIBITOR; HEMOGLOBIN A1C; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PLACEBO; SULFONYLUREA; TETRAHYDROLIPSTATIN; ANTIDIABETIC AGENT; ANTIOBESITY AGENT; CHOLESTEROL; LACTONE; LIPOPROTEIN;

ADULT; AGED; ARTICLE; BLOOD PRESSURE REGULATION; BODY WEIGHT; CALORIC INTAKE; CARDIOVASCULAR SYSTEM; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET; DOUBLE BLIND PROCEDURE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SYSTOLIC BLOOD PRESSURE; WEIGHT REDUCTION; BLOOD; BLOOD PRESSURE; COMPARATIVE STUDY; DIABETES MELLITUS; DRUG EFFECT; LOW CALORY DIET; MIDDLE AGED; PATHOPHYSIOLOGY; RACE; UNITED STATES;

ADULT; AGED; ANTI-OBESITY AGENTS; BLOOD GLUCOSE; BLOOD PRESSURE; BODY WEIGHT; CHOLESTEROL; CONTINENTAL POPULATION GROUPS; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 2; DIET, REDUCING; DOUBLE-BLIND METHOD; HUMANS; HYPOGLYCEMIC AGENTS; LACTONES; LIPOPROTEINS; METFORMIN; MIDDLE AGED; MISSOURI; OBESITY; PLACEBOS;

EID: 0036634125     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.25.7.1123     Document Type: Article

References (31)

1. American Diabetes Association: Nutrition recommendations and principles for people with diabetes mellitus (Position Statement). Diabetes Care 24:S44-S47, 2001
2. Wing R, Koeske R, Epstein L, Nowalk MP, Gooding W, Becker D: Long-term effects of modest weight loss in type II diabetic patients. Arch Intern Med 147:1749-1753, 1987
3. Lean ME, Powrie JK, Anderson AS, Garthwaite PH: Obesity, weight loss and prognosis in type 2 diabetes. Diabet Med 7:228-233, 1990
4. Williamson DF, Thompson TJ, Thun M, Flanders D, Pamuk E, Byers T: Intentional weight loss and mortality among overweight individuals with diabetes. Diabetes Care 23:1499-1504, 2000
5. Wing RR, Marcus MD, Epstein LH, Salata R: Type II diabetic subjects lose less weight than their overweight spouses. Diabetes Care 10:536-536, 1987
6. Guare JC, Wing RR, Grant A: Comparison of obese NIDDM and nondiabetic women: short- and long-term weight loss. Obes Res 3:329-335, 1995
7. Kudlacek S, Schemthaner G: The effect of insulin treatment on HbA1c, body weight and lipids in type 2 diabetic patients with secondary failure to sulfonylureas. Horm Metab Res 24:478-483, 1992
8. Edelman SV, Henry RR: Insulin therapy for normalizing glycosylated hemoglobin in type II diabetes. Diabetes Rev 3:308-334, 1995
9. Fuchtenbusch M, Standl E, Schatz H: Clinical efficacy of new thiazolidinediones and glinides in the treatment of type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 108:151-163, 2000
10. De Fronzo RA, Goodman AM: Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 333:541-549, 1995
11. Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE: Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med 333:550-554, 1995
12. Johansen K: Efficacy of metformin in the treatment of NIDDM: a meta-analysis. Diabetes Care 22:33-37, 1999
13. UK Prospective Diabetes Study Group: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352:854-865, 1998
14. Hollander PA, Elbein SC, Hirsch IB, Kelley D, McGill J, Taylor T, Weiss SR, Crockett SE, Kaplan RA, Comstock J, Lucas CP, Lodewick PA, Canovatchel W, Chung J, Hauptman J: Role of orlistat in the treatment of obese patients with type 2 diabetes. Diabetes Care 21:1288-1294, 1998
15. Fujioka K, Seaton TB, Rowe E, Jelinek CA, Raskin P, Lebovitz HE, Weinstein SP: Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus. Diabetes Obes Metab 2:175-187, 2000
16. Sjöstrōm L, Rissanen A, Andersen T, Boldrin M, Golay A, Koppeschaar HP, Krempf M: Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet 352:167-172, 1998
17. Davidson MH, Hauptman J, DiGirolamo M, Foreyt JP, Halsted CH, Heber D, Heimburger DC, Lucas CP, Robbins DC, Chung J, Heymsfield SB: Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat. JAMA 281:235-242, 1999
18. Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, Pitkin R, Rennie D, Schulz KF, Simel D, Stroup DF: Improving the quality of reporting of randomized controlled trials. JAMA 276:637-639, 1996
19. Genuth S: Implications of the United Kingdom prospective diabetes study for patients with obesity and type 2 diabetes. Obes Res 8:198-201, 2000
20. Lee A, Morley JE: Metformin decreases food consumption and induces weight loss in subjects with obesity with type II non-insulin-dependent diabetes. Obes Res 6:47-53, 1998
21. Hery RR, Scheaffer L, Olefsky JM: Glycemic effects of intensive caloric restriction and isocaloric refeeding in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 61:917-925, 1985
22. Kelley DE, Wing R, Buonocore C, Sturis J, Polonsky K, Fitzsimmons M: Relative effects of calorie restriction and weight loss in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 77:1287-1293, 1993
23. Iwamoto Y, Kosaka K, Kuzuya T, Akanuma Y, Shigeta Y, Kaneko T: Effects of troglitazone: a new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy. Diabetes Care 19:151-156, 1996
24. Kumar S, Boulton AJ, Beck-Nielsen H, Berthezene F, Muggeo M, Persson B, Spinas GA, Donghue S, Lettis S, Stewart-Lung P: Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients: Troglitazone Study Group. Diabetologia 39:701-709, 1996
25. Coniff RF, Shapiro JA, Seaton TB, Bray GA: Multicenter, placebo-controlled trial comparing acarbose (Bay g5421) with placebo, tolbutamide, and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus. Am J Med 48:443-451, 1995
26. Ghazzi MN, Perez JE, Antonucci TK, Driscoll JH, Huang SM, Faja BW, Whitcomb RW: Cardiac and glycemic benefits of troglitazone treatment in NIDDM: the Troglitazone Study Group. Diabetes 46:433-439, 1997
27. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321:405-412, 2000
28. DeFronzo RA: Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 131:281-303, 1999
29. Kaye TB: Triple oral antidiabetic therapy. J Diabetes Complications 12:311-313, 1998
30. Mittendorfer B, Ostlund R, Patterson BW, Klein S: Orlistat inhibits cholesterol absorption (Abstract). Obes Res 8 (Suppl. 1): 43S, 2000
31. Dunn CJ, Peters DH: Metformin: a review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes mellitus. Drugs 49:721-749, 1995